Short-term effect of COX-2 selective inhibitor as an adjunct for the treatment of periodontal disease-a clinical double-blind study in humans

Brazilian Dental Journal

Volumn 19, Issue 4, 2008, Pages 323-328

  Pinho, Márcia de Noronha ^a   Pereira, Leonardo Bíscaro ^a   de Souza, Sérgio Luís Scombatti ^a   Palioto, Daniela Bazan ^a   Grisi, Márcio Fernando de Moraes ^a   Novaes Jr , Arthur Belém ^a   Taba Jr , Mario ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adjunctive therapy; Inflammation; Periodontitis therapy; Prostaglandin

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; LOXOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLPROPIONIC ACID DERIVATIVE; PROSTAGLANDIN E2;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PERIODONTICS; PERIODONTITIS; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL; TIME; TOOTH PLAQUE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DENTAL PLAQUE INDEX; DENTAL SCALING; DINOPROSTONE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIODONTAL INDEX; PERIODONTITIS; PHENYLPROPIONATES; TIME FACTORS;

EID: 63249097701     PISSN: 01036440     EISSN: 18064760     Source Type: Journal    
DOI: 10.1590/s0103-64402008000400007     Document Type: Article

References (20)

1. Noguchi K, Ishikawa I. The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease. Periodontol 2000 2007;43:85-101.
2. Vardar S, Baylas H, Huseyinov A. Effects of selective cyclooxygenase-2 inhibition on gingival tissue levels of prostaglandin E2 and prostaglandin F2alpha and clinical parameters of chronic periodontitis. J Periodontol 2003;74:57-63.
3. Reynolds MA, Prudêncio A, Aichelmann-Reidy ME, Woodward K, Uhrich KE. Non-steroidal antiinflammatory drug (NSAID)-derived poly(anhydride-esters) in bone and periodontal regeneration. Curr Drug Deliv 2007;4:233-239.
4. de Queiroz AC, Taba M Jr, O'Connell PA, da Nóbrega PB, Costa PP, Kawata VK et al. Inflammation markers in healthy and periodontitis patients: a preliminary data screening. Braz Dent J 2008;19:3-8.
5. Kirkwood KL, Cirelli JA, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007;43:294-315.
6. Tipton DA, Flynn JC, Stein SH, Dabbous M. Cyclooxygenase-2 inhibitors decrease interleukin-1beta-stimulated prostaglandin E2 and IL-6 production by human gingival fibroblasts. J Periodontol 2003;74:1754-1763.
7. Offenbacher S, Williams RC, Jeffcoat MK, Howell TH, Odle BM, Smith MA. et al. Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss. J Periodontal Res 1992;27:207-213.
8. Taiyeb Ali TB, Waite IM. The effect of systemic ibuprofen on gingival inflammation in humans. J Clin Periodontol 1993;20:723-728.
9. Jeffcoat MK, Reddy MS, Haigh S, Buchanan W, Doyle MJ, Meredith MP. A comparison of topical ketorolac, systemic flurbiprofen, and placebo for the inhibition of bone loss in adult periodontitis. J Periodontol 1995;66:329-338.
10. D'Aiuto F, Ready D, Parkar M, Tonetti MS. Relative contribution of patient-, tooth-, and site-associated variability on the clinical outcomes of subgingival debridement. I. Probing depths. J Periodontol 2005;76:398-405.
11. Haffajee AD, Thompson M, Torresyap G, Guerrero D, Socransky SS. Efficacy of manual and powered toothbrushes (I). Effect on clinical parameters. J Clin Periodontol 2001;28:937-946.
12. Heasman PA, Seymour RA, Kelly PJ. The effect of systemically-administered flurbiprofen as an adjunct to toothbrushing on the resolution of experimental gingivitis. J Clin Periodontol 1994;21:166-170.
13. Paquette DW, Lawrence HP, McCombs GB, Wilder R, Binder TA, Troullos E. et al. Pharmacodynamic effects of ketoprofen on crevicular fluid prostanoids in adult periodontitis. J Clin Periodontol 2000;27:558-566.
14. Kuehn BM. FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs. Jama 2005;293:1571-1572.
15. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
16. Offenbacher S, Odle BM, Braswell LD, Johnson HG, Hall CM, McClure H. et al. Changes in cyclooxygenase metabolites in experimental periodontitis in Macaca mulatta. J Periodontal Res 1989;24:63-74.
17. Heasman PA, Seymour RA, Boston PF. The effect of a topical non-steroidal antiinflammatory drug on the development of experimental gingivitis in man. J Clin Periodontol 1989;16:353-358.
18. Williams RC, Jeffcoat MK, Howell TH, Rolla A, Stubbs D, Teoh KW. et al. Altering the progression of human alveolar bone loss with the non-steroidal antiinflammatory drug flurbiprofen. J Periodontol 1989;60:485-490.
19. Holzhausen MC, Rossa Junior E, Marcantonio Junior PO, Nassar DM, Spolidorio LC. Effect of selective cyclooxygenase-2 inhibition on the development of ligatureinduced periodontitis in rats. J Periodontol 2002;73:1030-1036.
20. Vardar S, Buduneli E, Baylas H, Berdeli AH, Buduneli N, Atilla G. Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats. J Periodontol 2005;76:99-106.